Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
| Status: |
In progress |
| Expected date of issue: |
June 2012 |
| Referral date: |
May 2011 |
| Wave: |
26 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Peter Littlejohns
|
| Technical Lead: |
Matthew Dyer
|
| Communications manager: |
Alice Law
|
| Project manager: |
Jeremy Powell
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
23 September 2011 |
| 1st appraisal committee meeting: |
05 January 2012 |
| 2nd appraisal committee meeting |
03 April 2012 |
Consultees and commentators
|
| Consultees |
Commentators (no right to submit or appeal) |
|
Manufacturers/sponsors
Patient/carer groups
- Macmillan Cancer Support
- PCaSO – Prostate Cancer Network
- Prostate Cancer Charity
- Prostate Cancer Support Federation
Professional groups
- British Association of Urological Surgeons
- British Uro-Oncology Group
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Physicians
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society
Others
- Department of Health
- NHS Hertfordshire
- NHS Bradford and Airedale
- Welsh Government
|
General
- British National Formulary
- Commissioning Support Appraisals Service
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
Comparator manufacturers
Relevant research groups
- MRC Clinical Trials Unit
- Prostate Action
- Evidence Review Group
- Warwick Evidence
- National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
- National Collaborating Centre for Cancer
Associated public health groups
|
|
Key documents
This page was last updated: 18 May 2012
